Maze Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The following table presents fees for professional audit services and other services rendered to us by Ernst & Young LLP for our fiscal years ended December 31, 2024 and 2023.
| Year Ended December 31, | ||
|---|---|---|
| Description of Services Provided by EY | 2024 | 2023 |
| Audit fees (1) | $1,950,000 | $525,000 |
| Audit related fees | — | — |
| Tax fees(2) | 40,000 | — |
| All other fees(3) | — | 2,000 |
| Total fees | $1,990,000 | $527,000 |
(1)
Audit fees consist of fees for professional services rendered in connection with the annual audit of our financial statements and review of our interim financial statements and services normally provided in connection with documents filed with the U.S. Securities and Exchange Commission. For the year ended December 31, 2024, the audit fees included professional services rendered in connection with the Form S-1 related to our initial public offering.
(2)
Tax fees for year ended December 31, 2024 consists of tax compliance services.
(3)
All Other Fees consists of an online accounting tool subscription paid to Ernst & Young Product Sales LLP.
Our audit committee has established a policy governing our use of the services of our independent registered public accounting firm. Under the policy, our audit committee is required to pre-approve all audit and permissible non-audit services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair such accounting firm’s independence. All fees paid to Ernst & Young LLP for our fiscal years ended December 31, 2023 and 2024 were pre-approved by our audit committee.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.